Eribulin Versus S1 As First- or Second-Line Chemotherapy to Assess Health-related Quality of Life and Overall Survival in HER2-negative Metastatic Breast Cancer (RESQ Study): a Non-Inferiority, Randomized Controlled Trial
CANCER RESEARCH(2023)
AI 理解论文
溯源树
样例

生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要